Wolverine Trading’s BridgeBio Pharma BBIO Stock Holding History

Wolverine Trading’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.59M	Buy	49,886 +16,564	+50%	+$808K	﹤0.01%	1950
2025 Q2	$1.49M	Sell	33,322 -1,143	-3%	-$41.6K	﹤0.01%	1934
2025 Q1	$1.21M	Sell	34,465 -6,528	-16%	-$220K	﹤0.01%	2062
2024 Q4	$1.12M	Buy	40,993 +21,859	+114%	+$565K	﹤0.01%	2544
2024 Q3	$477K	Buy	19,134 +6,124	+47%	+$161K	﹤0.01%	3103
2024 Q2	$330K	Sell	13,010 -4,516	-26%	-$123K	﹤0.01%	3287
2024 Q1	$542K	Buy	17,526 +6,048	+53%	+$206K	﹤0.01%	2759
2023 Q4	$463K	Sell	11,478 -1,024	-8%	-$30.8K	﹤0.01%	3028
2023 Q3	$330K	Buy	+12,502	New	+$355K	﹤0.01%	3194
2021 Q2	–	Sell	-3,978	Closed	-$227K	–	5963
2021 Q1	$235K	Buy	+3,978	New	+$260K	﹤0.01%	4819

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's BBIO Position: Q3 2025 in Review

Wolverine Trading increased its BridgeBio Pharma (BBIO) stake by 50% in Q3 2025, buying an estimated $808K and bringing the position to 49,886 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1950.

Wolverine Trading first reported a position in BBIO in Q1 2021 and has held it in 10 quarters since. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Wolverine Trading held 49,886 shares of BridgeBio Pharma worth $2.59M as of Q3 2025.
Wolverine Trading bought 16,564 BridgeBio Pharma shares in Q3 2025, an estimated $808K.
BridgeBio Pharma made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1950 holding.
Wolverine Trading first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 10 quarters since.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.